Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies

scientific article

Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1016/J.DLD.2012.11.010
P698PubMed publication ID23280158
P5875ResearchGate publication ID234031575

P50authorAnna AlisiQ42430617
Valerio NobiliQ56507694
Sara CeccarelliQ58423082
P2093author name stringEvelina Moraru
Otilia E Frasinariu
P433issue7
P921main subjectliver diseaseQ929737
metabolic dysfunction–associated steatotic liver diseaseQ1546498
fatty liver diseaseQ6058862
P304page(s)543-551
P577publication date2012-12-29
P1433published inDigestive and Liver DiseaseQ15766194
P1476titleGut-liver axis and fibrosis in nonalcoholic fatty liver disease: an input for novel therapies
P478volume45

Reverse relations

cites work (P2860)
Q47965667Altered gut-liver axis and hepatic adiponectin expression in OSAS: novel mediators of liver injury in paediatric non-alcoholic fatty liver
Q38937960Beverage consumption and paediatric NAFLD.
Q55070198Crosstalk between the microbiome and epigenome: messages from bugs.
Q37149656Developmental programming of pediatric nonalcoholic fatty liver disease: redefining the"first hit".
Q51017336Endotoxin exposure and puberty in female rats: the role of nitric oxide and caspase-1 inhibition in neonates.
Q37636566Fatty liver in childhood
Q57295702Gut Microbiota's Relationship with Liver Disease and Role in Hepatoprotection by Dietary Natural Products and Probiotics
Q35147488Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan.
Q30887448Hepatic hemangioma in celiac patients: data from a large consecutive series
Q93016049Herbal drug discovery for the treatment of nonalcoholic fatty liver disease
Q28068832Implication of the intestinal microbiome in complications of cirrhosis
Q36062584Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation
Q39301952Long-term challenges and perspectives of pre-adolescent liver disease
Q35084719Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications
Q26769611Metabolic derivatives of alcohol and the molecular culprits of fibro-hepatocarcinogenesis: Allies or enemies?
Q52877979Microbiota Modulation With Synbiotic Decreases Liver Fibrosis in a High Fat Choline Deficient Diet Mice Model of Non-Alcoholic Steatohepatitis (NASH).
Q38397177Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies
Q48099354Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome.
Q36255920Nonstructural 5A Protein of Hepatitis C Virus Interferes with Toll-Like Receptor Signaling and Suppresses the Interferon Response in Mouse Liver
Q47805260PI3K inhibition protects mice from NAFLD by down-regulating CMKLR1 and NLRP3 in Kupffer cells
Q92738115Paediatricians play a key role in preventing early harmful events that could permanently influence the development of the gut microbiota in childhood
Q37592952Pediatric non-alcoholic fatty liver disease: an increasing public health issue.
Q57803934Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease
Q33714116Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis
Q36600936Subclinical-Dose Endotoxin Sustains Low-Grade Inflammation and Exacerbates Steatohepatitis in High-Fat Diet-Fed Mice
Q51089692Systematic Review of the Relation Between Intestinal Microbiota and Toll-Like Receptors in the Metabolic Syndrome: What Do We Know So Far?
Q26780509The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease
Q39099711The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications.
Q93350798The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Q41158897Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment.

Search more.